Alnylam Pharmaceuticals, Inc. (ALNY: Quote) announced that the U.S. Food & Drug Administration, or FDA, has provided Orphan Drug Designation to ALN-TTR02 as a therapeutic for the treatment of familial amyloidotic polyneuropathy, or FAP, one of the predominant clinical manifestations of transthyretin (TTR)-mediated amyloidosis, or ATTR.
Saraswathy Nochur, vice president, Regulatory Affairs and Quality Assurance at Alnylam, stated, "We believe RNAi therapeutics represent a novel and exciting approach for ATTR patients and have great potential to make a meaningful impact in the treatment of this devastating disease. We look forward to sharing Phase I clinical data from our ALN-TTR02 program early in the third quarter, and, assuming continued positive results, we plan to advance to a pivotal trial in 2013. Alnylam is committed to bringing this high impact medicine to patients afflicted with ATTR."
Click here to receive FREE breaking news email alerts for Alnylam Pharmaceuticals Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org